semaglutide

Details

Files
Generic Name:
semaglutide
Project Status:
Complete
Therapeutic Area:
Weight management
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Wegovy
Project Line:
Reimbursement Review
Project Number:
SR0725-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Novo Nordisk Canada Inc. requests that Wegovy (semaglutide injection) 2.4 mg is listed as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 35 kg/m2 or greater AND prediabetes.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Wegovy (semaglutide injection) 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openFebruary 09, 2022
Call for patient/clinician input closedApril 01, 2022
Clarification:

- Patient input submission received from Obesity Canada and the Canadian Liver Foundation (joint), Gastrointestinal Society, Diabetes Canada, and Obesity Matters

Submission receivedMarch 10, 2022
Submission acceptedMarch 24, 2022
Review initiatedMarch 25, 2022
Draft CADTH review report(s) provided to sponsor for commentJune 10, 2022
Deadline for sponsors commentsJune 21, 2022
CADTH review report(s) and responses to comments provided to sponsorJuly 15, 2022
Expert committee meeting (initial)July 27, 2022
Draft recommendation issued to sponsorAugust 10, 2022
Draft recommendation posted for stakeholder feedbackAugust 18, 2022
End of feedback periodSeptember 02, 2022
Clarification:

Deadline for patient groups and clinician groups to provide feedback on the draft recommendations is 06-Sep-2022

Final recommendation issued to sponsor and drug plansSeptember 16, 2022
Final recommendation postedOctober 04, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)September 30, 2022
CADTH review report(s) postedDecember 09, 2022